[논문]Roles of ginsenosides in sepsis

Tao Yu; Yidi Tang; Fenglan Zhang; Leiming Zhang

doi:10.1016/j.jgr.2022.05.004

[국내논문] Roles of ginsenosides in sepsis 원문보기

Journal of ginseng research = 高麗人參學會誌, v.47 no.1, 2023년, pp.1 - 8

Tao Yu (Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, School of Pharmacy, Yantai University) , Yidi Tang (Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, School of Pharmacy, Yantai University) , Fenglan Zhang (Yantai Yuhuangding Hospital, The Affiliated Hospital of Qingdao University) , Leiming Zhang (Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, School of Pharmacy, Yantai University)

Abstract ▼ AI-Helper

The herbal medication Panax ginseng Meyer has widespread use in China, Korea, and other parts of the world. The main constituents of ginseng are ginsenosides, which include over 30 different triterpene saponins. It has been found that ginsenosides and their metabolites including Rg1, compound K, Rb1, Re, Rg3, and Rg5 exert anti-inflammatory activities by binding to the glucocorticoid receptor, modulating inflammation-related signaling, including NF-κB and MAPK signaling, and reducing levels of proinflammatory cytokines. Here, we review the recent literature on the molecular actions of ginsenosides in sepsis, suggesting ways in which they may be used to prevent and treat the disease.

Keyword

표/그림 (5)

그림 Fig. 1. Overview of the pathogenesis of acute inflammation in sepsis. The binding of PAMPs, including peptidoglycans, flagellin, and LPS, to TLRs activates signaling pathways leading to the recruitment of IRAK4 and MyD88, resulting in IRF3 activation and IFN-I release. Activated TLRs act through MAPK, JNK, and ERK to modulate IKKs (IκB kinases), leading to IκBα phosphorylation. This promotes the release of NF-κB (including p50 and p65) from IκBα, allowing the protein to enter the nucleus where it promotes the expression of pro-inflammatory cytokine and chemokine genes. Inflammation is also enhanced by the secretion of inflammatory factors from cells. In addition, changes in K⁺ and Ca²⁺ flux and disruption of organelles such as the mitochondria, lysosomes, and trans-Golgi assembly, amongst other cellular disturbances, activate NLRP3 leading to formation of the inflammasome, ultimately leading to increased secretion of IL-18 and IL-1β. LPS, lipopolysaccharide; TLR-4, Toll-like receptor 4; IL, interleukin; TNFα, tumor necrosis factor-alpha; Myd88, myeloid differentiation primary response 88 protein; IRAK4, interleukin-1 receptor-associated kinase 4; IKK, IκB, kinase; MAPK, mitogen-activated protein kinase; ERK, extracellular regulated protein kinases; JNK, c-Jun N-terminal kinase; IRF3, Interferon regulatory factor 3; AP-1, activator protein-1; NLRP3, NOD-like receptor protein 3.
표 Table 1 Classification of ginsenosides.
표 Table 2 Summary of recent new drug candidates in sepsis.
표 Table 3 Summary of the therapeutic effects of ginsenoside against sepsis.
그림 Fig. 2. Potential actions of ginsenosides in COVID-19 treatment The proposed treatment targets NF-κB-mediated signaling that produces the cytokine storm. SARS-CoV-2 interacts with the angiotensin-converting enzyme 2 (ACE2) receptor and undergoes TMPRSS2-mediated endocytosis. The Toll-like receptors TLR7 and TLR8 are activated by the virus's RNA, leading to transcription of interferon-regulator factors (IRFs), such as IRF3 and IRF7. Ginsenosides can block the SARS-CoV-2-ACE2 interaction binding. Endosomal IRFs are also prevented from entering the nucleus, thus inhibiting IFN-I production. TLR activation also triggers, through different intermediates, IKK (IκB kinase) activation, leading to IκBa phosphorylation and the release of NF-κB. Ginsenosides can block this NF-κB activation and subsequent actions in promoting the expression of pro-inflammatory factors, including cytokines, chemokines, and cell adhesion molecules. NF-κB signaling is also promoted by raised levels of free Ang II in the serum resulting from lowered ACE2-induced degradation as a consequence of the interaction between ACE2 and the virus, leading ultimately to the release of IL-6. Thus, NF-κB-mediated inflammation leads to further NF-κB activation, termed the IL-6 amplifier (IL-6 AMP). Ginsenosides inhibit NFκB signaling, thus lowering the production of pro-inflammatory factors. SARS-CoV-2, COVID-19; LPS, lipopolysaccharide; Ang II，angiotensin II; TLR-4, Toll-like receptor 4; IL-1, interleukin-1; IL-6, interleukin-6; TNFα, tumor necrosis factor-alpha; Myd88, myeloid differentiation primary response 88 protein; IRAK4, interleukin-1 receptor-associated kinase 4; IKK, IκB kinase; IRF3/7, Interferon regulatory factor 3/7.

참고문헌 (100)

1 Shankar H.M. Phillips G.S. Levy M.L. Seymour C.W. Liu V.X. Deutschman C.S. Angus D.C. Rubenfeld G.D. Singer M. Sepsis Definitions task F. Developing a new definition and assessing new clinical criteria for septic shock: for the third international Consensus Definitions for sepsis and septic shock (Sepsis-3) JAMA 315 2016 775 787 26903336
2 Cecconi M. Evans L. Levy M. Rhodes A. Sepsis and septic shock Lancet 392 2018 75 87 29937192
3 Levi M. Schultz M. van der Poll T. Sepsis and thrombosis Semin Thromb Hemost 39 2013 559 566 23625756

상세보기
4 Rudd K.E. Johnson S.C. Agesa K.M. Shackelford K.A. Tsoi D. Kievlan D.R. Colombara D.V. Ikuta K.S. Kissoon N. Finfer S. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study Lancet 395 2020 200 211 31954465
5 Liu V. Escobar G.J. Greene J.D. Soule J. Whippy A. Angus D.C. Iwashyna T.J. Hospital deaths in patients with sepsis from 2 independent cohorts JAMA 312 2014 90 92 24838355

상세보기
6 Xie J. Wang H. Kang Y. Zhou L. Liu Z. Qin B. Ma X. Cao X. Chen D. Lu W. The epidemiology of sepsis in Chinese ICUs: a national cross-sectional survey Crit Care Med 48 2020 e209 e218 31804299

상세보기
7 Poston J.T. Koyner J.L. Sepsis associated acute kidney injury BMJ 364 2019 k4891
8 Strnad P. Tacke F. Koch A. Trautwein C. Liver - guardian, modifier and target of sepsis Nat Rev Gastroenterol Hepatol 14 2017 55 66 27924081

상세보기
9 Li H. Liu L. Zhang D. Xu J. Dai H. Tang N. Su X. Cao B. SARS-CoV-2 and viral sepsis: observations and hypotheses Lancet 395 2020 1517 1520 32311318
10 Im D.S. Pro-resolving effect of ginsenosides as an anti-inflammatory mechanism of Panax ginseng Biomolecules 10 2020

상세보기
11 Tian M. Li L.N. Zheng R.R. Yang L. Wang Z.T. Advances on hormone-like activity of Panax ginseng and ginsenosides Chin J Nat Med 18 2020 526 535 32616193
12 Yi Y.S. New mechanisms of ginseng saponin-mediated anti-inflammatory action via targeting canonical inflammasome signaling pathways J Ethnopharmacol 278 2021 114292 34089812

상세보기
13 Huang M. Cai S. Su J. The pathogenesis of sepsis and potential therapeutic targets Int J Mol Sci 20 2019
14 Bhan C. Dipankar P. Chakraborty P. Sarangi P.P. Role of cellular events in the pathophysiology of sepsis Inflamm Res 65 2016 853 868 27392441
15 Raymond S.L. Holden D.C. Mira J.C. Stortz J.A. Loftus T.J. Mohr A.M. Moldawer L.L. Moore F.A. Larson S.D. Efron P.A. Microbial recognition and danger signals in sepsis and trauma Biochim Biophys Acta (BBA) - Mol Basis Dis 1863 2017 2564 2573
16 Kawai T. Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors Nat Immunol 11 2010 373 384 20404851

상세보기
17 Kawai T. Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity Immunity 34 2011 637 650 21616434

상세보기
18 Annane D. Bellissant E. Cavaillon J.M. Septic shock Lancet 365 2005 63 78 15639681
19 Schroder K. Tschopp J. The inflammasomes Cell 140 2010 821 832 20303873

상세보기
20 Swanson K.V. Deng M. Ting J.P. The NLRP3 inflammasome: molecular activation and regulation to therapeutics Nat Rev Immunol 19 2019 477 489 31036962

상세보기
21 Munoz-Planillo R. Kuffa P. Martinez-Colon G. Smith B.L. Rajendiran T.M. Nunez G. K(+) efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter Immunity 38 2013 1142 1153 23809161

상세보기
22 Murakami T. Ockinger J. Yu J. Byles V. McColl A. Hofer A.M. Horng T. Critical role for calcium mobilization in activation of the NLRP3 inflammasome Proc Natl Acad Sci U S A 109 2012 11282 11287 22733741

상세보기
23 Qiu Z. He Y. Ming H. Lei S. Leng Y. Xia Z.Y. Lipopolysaccharide (LPS) aggravates high glucose- and hypoxia/reoxygenation-induced injury through activating ROS-dependent NLRP3 inflammasome-mediated pyroptosis in H9C2 cardiomyocytes J Diabetes Res 2019 2019 8151836 30911553

상세보기
24 van der Poll T. van de Veerdonk F.L. Scicluna B.P. Netea M.G. The immunopathology of sepsis and potential therapeutic targets Nat Rev Immunol 17 2017 407 420 28436424

상세보기
25 Hagar J.A. Powell D.A. Aachoui Y. Ernst R.K. Miao E.A. Cytoplasmic LPS activates caspase-11: implications in TLR4-independent endotoxic shock Science 341 2013 1250 1253 24031018

상세보기
26 Deng M. Tang Y. Li W. Wang X. Zhang R. Zhang X. Zhao X. Liu J. Tang C. Liu Z. The endotoxin delivery protein HMGB1 mediates caspase-11-dependent lethality in sepsis Immunity 49 2018 740 753 e7 30314759
27 Liu J. Li S. Liu J. Liang B. Wang X. Wang H. Li W. Tong Q. Yi J. Zhao L. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients EBioMedicine 55 2020 102763 32361250

상세보기
28 Huang C. Wang Y. Li X. Ren L. Zhao J. Hu Y. Zhang L. Fan G. Xu J. Gu X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Lancet 395 2020 497 506 31986264
29 Rhodes A. Evans L.E. Alhazzani W. Levy M.M. Antonelli M. Ferrer R. Kumar A. Sevransky J.E. Sprung C.L. Nunnally M.E. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016 Intensive Care Med 43 2017 304 377 28101605

상세보기
30 Opal S.M. The evolution of the understanding of sepsis, infection, and the host response: a brief history Crit Care Clin 25 2009 637 663 [vii] 19892245

상세보기
31 Eisen D.P. Manifold beneficial effects of acetyl salicylic acid and nonsteroidal anti-inflammatory drugs on sepsis Intensive Care Med 38 2012 1249 1257 22531881

상세보기
32 Vandewalle J. Libert C. Glucocorticoids in sepsis: to Be or not to Be Front Immunol 11 2020 1318 32849493
33 Heming N. Lamothe L. Ambrosi X. Annane D. Emerging drugs for the treatment of sepsis Expet Opin Emerg Drugs 21 2016 27 37
34 Dellinger R.P. Levy M.M. Rhodes A. Annane D. Gerlach H. Opal S.M. Sevransky J.E. Sprung C.L. Douglas I.S. Jaeschke R. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012 Crit Care Med 41 2013 580 637 23353941

상세보기
35 Marik P.E. The role of glucocorticoids as adjunctive treatment for sepsis in the modern era Lancet Respir Med 6 2018 793 800 30006071

상세보기
36 Annane D. Renault A. Brun-Buisson C. Megarbane B. Quenot J.P. Siami S. Cariou A. Forceville X. Schwebel C. Martin C. Hydrocortisone plus fludrocortisone for adults with septic shock N Engl J Med 378 2018 809 818 29490185

상세보기
37 Venkatesh B. Finfer S. Cohen J. Rajbhandari D. Arabi Y. Bellomo R. Billot L. Correa M. Glass P. Harward M. Adjunctive glucocorticoid therapy in patients with septic shock N Engl J Med 378 2018 797 808 29347874

상세보기
38 Kadmiel M. Cidlowski J.A. Glucocorticoid receptor signaling in health and disease Trends Pharmacol Sci 34 2013 518 530 23953592

상세보기
39 Rhen T. Cidlowski J.A. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs N Engl J Med 353 2005 1711 1723 16236742

상세보기
40 Lasa M. Abraham S.M. Boucheron C. Saklatvala J. Clark A.R. Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38 Mol Cell Biol 22 2002 7802 7811 12391149

상세보기
41 Dendoncker K. Libert C. Glucocorticoid resistance as a major drive in sepsis pathology Cytokine Growth Factor Rev 35 2017 85 96 28479044
42 Wilkinson L. Verhoog N.J.D. Louw A. Disease- and treatment-associated acquired glucocorticoid resistance Endocr Connect 7 2018 R328 R349 30352419

상세보기
43 Shibata S. Fujita M. Itokawa H. Tanaka O. Ishii T. Studies on the constituents of Japanese and Chinese crude drugs. Xi. Panaxadiol, a sapogenin of ginseng roots Chem Pharm Bull (Tokyo) 11 1963 759 761 14068710
44 Yuan Q. Jiang Y.W. Ma T.T. Fang Q.H. Pan L. Attenuating effect of Ginsenoside Rb1 on LPS-induced lung injury in rats J Inflamm 11 2014 40
45 Yu S. Zhou X. Li F. Xu C. Zheng F. Li J. Zhao H. Dai Y. Liu S. Feng Y. Microbial transformation of ginsenoside Rb1, Re and Rg1 and its contribution to the improved anti-inflammatory activity of ginseng Sci Rep 7 2017 138 28273939

상세보기
46 Joh E.H. Lee I.A. Jung I.H. Kim D.H. Ginsenoside Rb1 and its metabolite compound K inhibit IRAK-1 activation--the key step of inflammation Biochem Pharmacol 82 2011 278 286 21600888

상세보기
47 Shaukat A. Guo Y.F. Jiang K. Zhao G. Wu H. Zhang T. Yang Y. Guo S. Yang C. Zahoor A. Ginsenoside Rb1 ameliorates Staphylococcus aureus-induced Acute Lung Injury through attenuating NF-kappaB and MAPK activation Microb Pathog 132 2019 302 312 31059756
48 Wu L.L. Jia B.H. Sun J. Chen J.X. Liu Z.Y. Liu Y. Protective effects of ginsenoside Rb1 on septic rats and its mechanism Biomed Environ Sci 27 2014 300 303 24758759

상세보기
49 Hua F. Shi L. Zhou P. Phytochemicals as potential IKK-beta inhibitor for the treatment of cardiovascular diseases in plant preservation: terpenoids, alkaloids, and quinones Inflammopharmacology 28 2020 83 93 31487001
50 Lee I.A. Hyam S.R. Jang S.E. Han M.J. Kim D.H. Ginsenoside Re ameliorates inflammation by inhibiting the binding of lipopolysaccharide to TLR4 on macrophages J Agric Food Chem 60 2012 9595 9602 22849695

상세보기
51 Quan H.Y. Jin X.Y. Cui E.J. Zhang Q. Lipopolysaccharide-induced inflammation is inhibited by ginsenoside Re through NF-kappa B signaling in RAW264.7 cells and primary rat hepatocytes Lat Am J Pharm 38 2019 1969 1978
52 Chen R.C. Wang J. Yang L. Sun G.B. Sun X.B. Protective effects of ginsenoside Re on lipopolysaccharide-induced cardiac dysfunction in mice Food Funct 7 2016 2278 2287 27074714

상세보기
53 Lee J.H. Min D.S. Lee C.W. Song K.H. Kim Y.S. Kim H.P. Ginsenosides from Korean Red Ginseng ameliorate lung inflammatory responses: inhibition of the MAPKs/NF-kappaB/c-Fos pathways J Ginseng Res 42 2018 476 484 30337808
54 Ryu S.-J. Choi J. Lee J.-S. Choi H.-S. Yoon K.-Y. Hwang J.-H. Kim K. Lee B.-Y. Compound K inhibits the lipopolysaccharide-induced inflammatory responses in raw 264.7 cell line and zebrafish Appl Sci 8 2018
55 Liu Y. Perumalsamy H. Kang C.H. Kim S.H. Hwang J.S. Koh S.C. Yi T.H. Kim Y.J. Intracellular synthesis of gold nanoparticles by Gluconacetobacter liquefaciens for delivery of peptide CopA3 and ginsenoside and anti-inflammatory effect on lipopolysaccharide-activated macrophages Artif Cell Nanomed Biotechnol 48 2020 777 788
56 Yang C.S. Ko S.R. Cho B.G. Shin D.M. Yuk J.M. Li S. Kim J.M. Evans R.M. Jung J.S. Song D.K. The ginsenoside metabolite compound K, a novel agonist of glucocorticoid receptor, induces tolerance to endotoxin-induced lethal shock J Cell Mol Med 12 2008 1739 1753 18053081

상세보기
57 Nguyen T.L.L. Huynh D.T.N. Jin Y. Jeon H. Heo K.S. Protective effects of ginsenoside-Rg2 and -Rh1 on liver function through inhibiting TAK1 and STAT3-mediated inflammatory activity and Nrf2/ARE-mediated antioxidant signaling pathway Arch Pharm Res (Seoul) 44 2021 241 252
58 Park E.K. Choo M.K. Han M.J. Kim D.H. Ginsenoside Rh1 possesses antiallergic and anti-inflammatory activities Int Arch Allergy Immunol 133 2004 113 120 14739579

상세보기
59 Jung J.S. Kim D.H. Kim H.S. Ginsenoside Rh1 suppresses inducible nitric oxide synthase gene expression in IFN-gamma-stimulated microglia via modulation of JAK/STAT and ERK signaling pathways Biochem Biophys Res Commun 397 2010 323 328 20510882
60 Kim J. Ahn H. Han B.C. Lee S.H. Cho Y.W. Kim C.H. Hong E.J. An B.S. Jeung E.B. Lee G.S. Korean red ginseng extracts inhibit NLRP3 and AIM2 inflammasome activation Immunol Lett 158 2014 143 150 24418475

상세보기
61 Li J. Du J. Liu D. Cheng B. Fang F. Weng L. Wang C. Ling C. Ginsenoside Rh1 potentiates dexamethasone's anti-inflammatory effects for chronic inflammatory disease by reversing dexamethasone-induced resistance Arthritis Res Ther 16 2014 R106 24887434

상세보기
62 Lee W. Cho S.H. Kim J.E. Lee C. Lee J.H. Baek M.C. Song G.Y. Bae J.S. Suppressive effects of ginsenoside Rh1 on HMGB1-mediated septic responses Am J Chin Med 47 2019 119 133 30630344

상세보기
63 Hsieh Y.H. Deng J.S. Chang Y.S. Huang G.J. Ginsenoside Rh2 ameliorates lipopolysaccharide-induced acute lung injury by regulating the TLR4/PI3K/Akt/mTOR, raf-1/MEK/ERK, and keap1/nrf2/HO-1 signaling pathways in mice Nutrients 10 2018

상세보기
64 Baatar D. Siddiqi M.Z. Im W.T. Ul Khaliq N. Hwang S.G. Anti-inflammatory effect of ginsenoside Rh2-mix on lipopolysaccharide-stimulated RAW 264.7 murine macrophage cells J Med Food 21 2018 951 960 30239266
65 Fu B.D. Bi W.Y. He C.L. Zhu W. Shen H.Q. Yi P.F. Wang L. Wang D.C. Wei X.B. Sulfated derivatives of 20(S)-ginsenoside Rh2 and their inhibitory effects on LPS-induced inflammatory cytokines and mediators Fitoterapia 84 2013 303 307 23266729

상세보기
66 Bi W.Y. Fu B.D. Shen H.Q. Wei Q. Zhang C. Song Z. Qin Q.Q. Li H.P. Lv S. Wu S.C. Sulfated derivative of 20(S)-ginsenoside Rh2 inhibits inflammatory cytokines through MAPKs and NF-kappa B pathways in LPS-induced RAW264.7 macrophages Inflammation 35 2012 1659 1668 22614119

상세보기
67 Zou Y. Tao T. Tian Y. Zhu J. Cao L. Deng X. Li J. Ginsenoside Rg1 improves survival in a murine model of polymicrobial sepsis by suppressing the inflammatory response and apoptosis of lymphocytes J Surg Res 183 2013 760 766 23478085

상세보기
68 Ning C. Gao X. Wang C. Huo X. Liu Z. Sun H. Yang X. Sun P. Ma X. Meng Q. Protective effects of ginsenoside Rg1 against lipopolysaccharide/d-galactosamine-induced acute liver injury in mice through inhibiting toll-like receptor 4 signaling pathway Int Immunopharm 61 2018 266 276
69 Wang Q.L. Yang L. Peng Y. Gao M. Yang M.S. Xing W. Xiao X.Z. Ginsenoside Rg1 regulates SIRT1 to ameliorate sepsis-induced lung inflammation and injury via inhibiting endoplasmic reticulum stress and inflammation Mediat Inflamm 2019 2019 6453296
70 Luo M. Yan D. Sun Q. Tao J. Xu L. Sun H. Zhao H. Ginsenoside Rg1 attenuates cardiomyocyte apoptosis and inflammation via the TLR4/NF-kB/NLRP3 pathway J Cell Biochem 121 2020 2994 3004 31709615

상세보기
71 Song Y. Zhao F. Zhang L. Du Y. Wang T. Fu F. Ginsenoside Rg1 exerts synergistic anti-inflammatory effects with low doses of glucocorticoids in vitro Fitoterapia 91 2013 173 179 24035860

상세보기
72 Du J. Cheng B. Zhu X. Ling C. Ginsenoside Rg1, a novel glucocorticoid receptor agonist of plant origin, maintains glucocorticoid efficacy with reduced side effects J Immunol 187 2011 942 950 21666059
73 Kim T.W. Joh E.H. Kim B. Kim D.H. Ginsenoside Rg5 ameliorates lung inflammation in mice by inhibiting the binding of LPS to toll-like receptor-4 on macrophages Int Immunopharm 12 2012 110 116
74 Kim J.E. Lee W. Yang S. Cho S.H. Baek M.C. Song G.Y. Bae J.S. Suppressive effects of rare ginsenosides, Rk1 and Rg5, on HMGB1-mediated septic responses Food Chem Toxicol 124 2019 45 53 30496780

상세보기
75 Shin Y.M. Jung H.J. Choi W.Y. Lim C.J. Antioxidative, anti-inflammatory, and matrix metalloproteinase inhibitory activities of 20(S)-ginsenoside Rg3 in cultured mammalian cell lines Mol Biol Rep 40 2013 269 279 23054007

상세보기
76 Yoon S.J. Park J.Y. Choi S. Lee J.B. Jung H. Kim T.D. Yoon S.R. Choi I. Shim S. Park Y.J. Ginsenoside Rg3 regulates S-nitrosylation of the NLRP3 inflammasome via suppression of iNOS Biochem Biophys Res Commun 463 2015 1184 1189 26086107

상세보기
77 Shi Y. Wang H. Zheng M. Xu W. Yang Y. Shi F. Ginsenoside Rg3 suppresses the NLRP3 inflammasome activation through inhibition of its assembly Faseb J 34 2020 208 221 31914640

상세보기
78 Xin C. Kim J. Quan H. Yin M. Jeong S. Choi J.I. Jang E.A. Lee C.H. Kim D.H. Bae H.B. Ginsenoside Rg3 promotes Fc gamma receptor-mediated phagocytosis of bacteria by macrophages via an extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent mechanism Int Immunopharm 77 2019 105945
79 Lee B. Sur B. Park J. Kim S.H. Kwon S. Yeom M. Shim I. Lee H. Hahm D.H. Ginsenoside rg3 alleviates lipopolysaccharide-induced learning and memory impairments by anti-inflammatory activity in rats Biomol Ther (Seoul) 21 2013 381 390 24244826
80 Xing W. Yang L. Peng Y. Wang Q. Gao M. Yang M. Xiao X. Ginsenoside Rg3 attenuates sepsis-induced injury and mitochondrial dysfunction in liver via AMPK-mediated autophagy flux Biosci Rep 37 2017

상세보기
81 Yang J. Li S. Wang L. Du F. Zhou X. Song Q. Zhao J. Fang R. Ginsenoside Rg3 attenuates lipopolysaccharide-induced acute lung injury via MerTK-dependent activation of the PI3K/AKT/mTOR pathway Front Pharmacol 9 2018 850 30116194

상세보기
82 Beltran-Garcia J. Osca-Verdegal R. Pallardo F.V. Ferreres J. Rodriguez M. Mulet S. Sanchis-Gomar F. Carbonell N. Garcia-Gimenez J.L. Oxidative stress and inflammation in COVID-19-associated sepsis: the potential role of anti-oxidant therapy in avoiding disease progression Antioxidants 9 2020

상세보기
83 Zhang D. Hamdoun S. Chen R. Yang L. Ip C.K. Qu Y. Li R. Jiang H. Yang Z. Chung S.K. Identification of natural compounds as SARS-CoV-2 entry inhibitors by molecular docking-based virtual screening with bio-layer interferometry Pharmacol Res 172 2021 105820 34403732

상세보기
84 Mehta P. McAuley D.F. Brown M. Sanchez E. Tattersall R.S. Manson J.J. Hlh Across Speciality Collaboration Uk COVID-19: consider cytokine storm syndromes and immunosuppression Lancet 395 2020 1033 1034 32192578
85 Park H.H. Kim H.N. Kim H. Yoo Y. Shin H. Choi E.Y. Bae J.S. Lee W. Acetylated K676 TGFBIp as a severity diagnostic blood biomarker for SARS-CoV-2 pneumonia Sci Adv 6 2020

상세보기
86 Park H.H. Kim H. Lee H.S. Seo E.U. Kim J.E. Lee J.H. Mun Y.H. Yoo S.Y. An J. Yun M.Y. PEGylated nanoparticle albumin-bound steroidal ginsenoside derivatives ameliorate SARS-CoV-2-mediated hyper-inflammatory responses Biomaterials 273 2021 120827 33910079

상세보기
87 Xiao Q. Zhang S. Yang C. Du R. Zhao J. Li J. Xu Y. Qin Y. Gao Y. Huang W. Ginsenoside Rg1 ameliorates palmitic acid-induced hepatic steatosis and inflammation in HepG2 cells via the AMPK/NF-kappaB pathway Internet J Endocrinol 2019 2019 7514802
88 Brasier A.R. The nuclear factor-kappaB-interleukin-6 signalling pathway mediating vascular inflammation Cardiovasc Res 86 2010 211 218 20202975
89 Zhou P. Yang X.L. Wang X.G. Hu B. Zhang L. Zhang W. Si H.R. Zhu Y. Li B. Huang C.L. A pneumonia outbreak associated with a new coronavirus of probable bat origin Nature 579 2020 270 273 32015507
90 Hirano T. Murakami M. COVID-19: a new virus, but a familiar receptor and cytokine release syndrome Immunity 52 2020 731 733 32325025

상세보기
91 Divani A.A. Andalib S. Di Napoli M. Lattanzi S. Hussain M.S. Biller J. McCullough L.D. Azarpazhooh M.R. Seletska A. Mayer S.A. Coronavirus disease 2019 and stroke: clinical manifestations and pathophysiological insights J Stroke Cerebrovasc Dis 29 2020 104941 32689643

상세보기
92 Vignon P. Laterre P.F. Daix T. Francois B. New agents in development for sepsis: any reason for hope? Drugs 80 2020 1751 1761 32951149
93 Ren J.L. Zhang A.H. Wang X.J. Corrigendum to "traditional Chinese medicine for COVID-19 treatment" [pharmacol. Res. 155 (2020) 104743] Pharmacol Res 155 2020 104768 32222346

상세보기
94 Yu X.Q. Robbie G.J. Wu Y. Esser M.T. Jensen K. Schwartz H.I. Bellamy T. Hernandez-Illas M. Jafri H.S. Safety, tolerability, and pharmacokinetics of MEDI4893, an investigational, extended-half-life, anti-Staphylococcus aureus alpha-toxin human monoclonal antibody, in healthy adults Antimicrob Agents Chemother 61 2017

상세보기
95 Ali S.O. Yu X.Q. Robbie G.J. Wu Y. Shoemaker K. Yu L. DiGiandomenico A. Keller A.E. Anude C. Hernandez-Illas M. Phase 1 study of MEDI3902, an investigational anti-Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults Clin Microbiol Infect 25 2019 629 e1 e6
96 Vincent J.L. Francois B. Zabolotskikh I. Daga M.K. Lascarrou J.B. Kirov M.Y. Pettila V. Wittebole X. Meziani F. Mercier E. Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: the SCARLET randomized clinical trial JAMA 321 2019 1993 2002 31104069

상세보기
97 Geven C. Blet A. Kox M. Hartmann O. Scigalla P. Zimmermann J. Marx G. Laterre P.F. Mebazaa A. Pickkers P. A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2) BMJ Open 9 2019 e024475
98 Leentjens J. Kox M. Koch R.M. Preijers F. Joosten L.A. van der Hoeven J.G. Netea M.G. Pickkers P. Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study Am J Respir Crit Care Med 186 2012 838 845 22822024

상세보기
99 François B. Wittebole X. Ferrer R. Mira J.-P. Dugernier T. Gibot S. Derive M. Olivier A. Cuvier V. Witte S. Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial Intensive Care Med 46 2020 1425 1437 32468087

상세보기
100 Francois B. Jeannet R. Daix T. Walton A.H. Shotwell M.S. Unsinger J. Monneret G. Rimmele T. Blood T. Morre M. Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial JCI Insight 3 2018

상세보기

활용도 분석정보

상세보기

다운로드

내보내기

활용도 Top5 논문

해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.

표제어: PCR

동의어: Packet Collision Rate

용어 설명 출처 목록 (6)

용어 설명: PCR은 세균 특이성이 있는 primer를 이용하여 적은 수의 세균이 있을지라도 쉽게 검출할 수 있는 유용한 방법이며, 이를 이용하여 구강 내 치면세균막이나 타액에서 직접 세균을 검출할 수 있게 되었다[8].

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증